BioCryst to Report Third Quarter 2021 Financial Results on November 3
RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…
Börse:
14,158€
1,49%
Echtzeit-Aktienkurs BioCryst Pharmaceuticals Inc.
Bid:
13,942€
Ask:
14,374€
Nachrichten zur BioCryst Pharmaceuticals Inc. Aktie
Insiderhandel: Aufsichtsrat verkauft Aktien von BioCryst Pharmaceuticals im Wert von 1.617.000$
Hutson, Nancy J. - Aufsichtsrat - Tag der Transaktion: 2021-10-15...…
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Oct. 04, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…
BioCryst Pharmaceuticals director acquires 53K shares
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BIOCRYST PHARMACEUTICALS INC: 8-K Report
FORM 8-K...…
Insiderhandel: Aufsichtsrat verkauft Aktien von BioCryst Pharmaceuticals im Wert von 92.100$
Lee, Kenneth B Jr - Aufsichtsrat - Tag der Transaktion: 2021-09-13...…
What Wall Street Still Has Wrong. BioCryst To Become Next Rare Disease Giant
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the…
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…
BioCryst announces exercise of option by U.S. to procure an additional batch of RAPIVAB
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst Say U.S. Government Excercises Option to Buy Rapivab Doses
BioCryst Say U.S. Government Excercises Option to Buy Rapivab Doses...…
BIOCRYST PHARMACEUTICALS INC: 8-K Report
FORM 8-K...…
BioCryst Appoints Dr. Steven Galson to Board of Directors
RESEARCH TRIANGLE PARK, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the…
BioCryst Announces Acceptance of Regulatory Applications for ORLADEYO® (berotralstat) by Health Canada and Swissmedic
RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that…
BioCryst fends off Takeda in hereditary angioedema
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst Stock Jumps After Pulling Out $200M Equity Raise
read more...…
BioCryst recovers amid social media buzz after cancelled stock offering
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst withdraws previous stock offering
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst Withdraws Public Offering
RESEARCH TRIANGLE PARK, N.C., Aug. 10, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today that…
BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants
RESEARCH TRIANGLE PARK, N.C., Aug. 09, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today that…
BIOCRYST PHARMACEUTICALS INC: 8-K Report
FORM 8-K...…
BIOCRYST PHARMACEUTICALS INC: 10-Q Report
FORM 10-Q...…
Jeffferies downgrades BioCryst to hold on uncertainty over Factor D inhibitor indications
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call Presentation
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst Pharmaceuticals (BCRX) Q2 2021 Earnings Call Transcript
BCRX earnings call for the period ending June 30, 2021....…
Why BioCryst Pharmaceuticals Rose 8% on Thursday
The companys first commercial drug launch keeps exceeding expectations....…
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 2021 Results - Earnings Call Transcript
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst shares surge on ORLADEYO driven Q2 topline beat
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BIOCRYST PHARMACEUTICALS INC: 8-K Report
FORM 8-K...…
BioCryst rises as Cantor initiates with a bullish call citing potential of Orladeyo
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BIOCRYST PHARMACEUTICALS INC: 8-K Report
FORM 8-K...…
Unusual Options Activity Insight: BioCryst Pharmaceuticals
On Friday, shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) saw unusual options activity. After the option alert, the stock price moved up…
BioCryst to Report Second Quarter 2021 Financial Results on August 5
RESEARCH TRIANGLE PARK, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that…
BioCryst Pharmaceuticals - Orladeyo Revenue Will Drive Share Price
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Insiderhandel: Aufsichtsrat verkauft Aktien von BioCryst Pharmaceuticals im Wert von 78.450$
Abercrombie, George B. - Aufsichtsrat - Tag der Transaktion: 2021-07-15...…
BioCryst Outlines Pivotal Trial Designs For BCX9930 In Rare Blood Disorder
read more...…
BioCryst Pharma outlines designs for two BCX9930 trials as oral monotherapy for PNH patients
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst Announces Designs for REDEEM-1 and REDEEM-2 Pivotal Trials with BCX9930 as Oral Monotherapy for Patients with PNH
RESEARCH TRIANGLE PARK, N.C., July 15, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the…
BioCryst Shares 96-Week Orladeyo Data Highlighting 80% Reduction In HAE Attacks
read more...…
BioCryst Reports 96-week Data from APeX-2 Showing ORLADEYO®(berotralstat) Reduced HAE Attack Rate by 80 Percent from Baseline
—Multiple data presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2021 highlight durability of effect…
Up 126% in 2021, Could BioCryst Pharmaceuticals Go Even Higher?
Theres more than one opportunity for it to do so....…
KalVista and BioCryst fall after Intellia shows promise in gene editing
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst Announces Acceptance and Accelerated Review of the ORLADEYO™ (berotralstat) Marketing Application by the Israeli Ministry of Health
— Neopharm Ltd. selected as exclusive distribution and supply partner of ORLADEYO in Israel — — Neopharm Ltd. selected as…
BioCryst Pharmaceuticals: An Orphan Disease Innovator With More Upside
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioCryst launches ORLADEYO in Germany
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BIOCRYST PHARMACEUTICALS INC: 8-K Report
FORM 8-K...…
BIOCRYST PHARMACEUTICALS INC: 8-K Report
FORM 8-K...…
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., May 26, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the…
Is BioCryst a Good Stock to Buy Now?
This commercial-stage drugmaker trades for less than many of its clinical-stage peers....…
Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock?
Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately....…